Abstract
Recently, lncRNA DILC has been reported as a regulatory element in carcinogenesis of various tumors. Nevertheless, its impact on cancer immunity remains limited in breast cancer. The rationale of this study was to identify and correlate the impact of DILC and the PD-L1 inhibitor; Atezolizumab on the metastatic and oxidative function of PBMCs in tumor microenvironment (TME) of TNBC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
